DXSE:F:F-Xtrackers Stoxx Europe 600 Health Care Swap UCITS ETF 1C (EUR)

ETF | Others |

Last Closing

USD 218.8

Change

+1.00 (+0.46)%

Market Cap

N/A

Volume

N/A

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-01-22 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
PRAJ:F Amundi Index Solutions - Amund..

N/A

USD 139.20B
UIM5:F UBS (Lux) Fund Solutions - MSC..

+0.07 (+0.14%)

USD 114.13B
SXR8:F iShares Core S&P 500 UCITS ETF..

+4.82 (+0.78%)

USD 106.46B
ZPDJ:F SPDR® MSCI Japan UCITS ETF

+0.09 (+0.17%)

USD 100.12B
XDNY:F Xtrackers MSCI Japan ESG Scree..

+0.12 (+0.76%)

USD 63.18B
VUSA:F Vanguard Funds Public Limited ..

+1.09 (+0.99%)

USD 51.63B
VUAA:F Vanguard S&P 500 UCITS Acc

+1.09 (+0.98%)

USD 51.63B
SXRZ:F iShares VII PLC - iShares Nikk..

N/A

USD 51.11B
XJSE:F Xtrackers II - Japan Governmen..

-0.06 (-0.73%)

USD 43.12B
0ZC:F Zscaler Inc

+2.94 (+1.63%)

USD 37.92B

ETFs Containing DXSE:F

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 1.86% 52% F 51% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 1.86% 52% F 50% F
Trailing 12 Months  
Capital Gain 4.14% 35% F 49% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 4.14% 32% F 41% F
Trailing 5 Years  
Capital Gain 32.70% 62% D 64% D
Dividend Return N/A N/A N/A N/A N/A
Total Return 32.70% 61% D- 46% F
Average Annual (5 Year Horizon)  
Capital Gain 9.76% 68% D+ 64% D
Dividend Return 9.76% 66% D+ 57% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 8.59% 73% C 93% A
Risk Adjusted Return 113.63% 97% N/A 97% N/A
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (EUR)

Quarterly Financials (EUR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

What to not like:

There is nothing we particularly dislike